Follow
Zachary R Chalmers
Zachary R Chalmers
Verified email at northwestern.edu
Title
Cited by
Cited by
Year
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
ZR Chalmers, CF Connelly, D Fabrizio, L Gay, SM Ali, R Ennis, A Schrock, ...
Genome medicine 9, 1-14, 2017
28792017
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors
GM Frampton, SM Ali, M Rosenzweig, J Chmielecki, X Lu, TM Bauer, ...
Cancer discovery 5 (8), 850-859, 2015
7262015
Targeted next generation sequencing identifies markers of response to PD-1 blockade
DB Johnson, GM Frampton, MJ Rioth, E Yusko, Y Xu, X Guo, RC Ennis, ...
Cancer immunology research 4 (11), 959-967, 2016
4672016
Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations
AB Schrock, GM Frampton, J Suh, ZR Chalmers, M Rosenzweig, ...
Journal of Thoracic Oncology 11 (9), 1493-1502, 2016
3752016
Small-molecule MYC inhibitors suppress tumor growth and enhance immunotherapy
H Han, AD Jain, MI Truica, J Izquierdo-Ferrer, JF Anker, B Lysy, V Sagar, ...
Cancer cell 36 (5), 483-497. e15, 2019
2862019
Comprehensive genomic profiling of 282 pediatric low‐and high‐grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures
A Johnson, E Severson, L Gay, JA Vergilio, J Elvin, J Suh, S Daniel, ...
The oncologist 22 (12), 1478-1490, 2017
2042017
Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing
CH Chung, VB Guthrie, DL Masica, C Tokheim, H Kang, J Richmon, ...
Annals of oncology 26 (6), 1216-1223, 2015
1902015
Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes
J Chmielecki, KE Hutchinson, GM Frampton, ZR Chalmers, A Johnson, ...
Cancer discovery 4 (12), 1398-1405, 2014
1712014
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In …
SM Ali, T Hensing, AB Schrock, J Allen, E Sanford, K Gowen, A Kulkarni, ...
The oncologist 21 (6), 762-770, 2016
1392016
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015; 5: 850–859 …
GM Frampton, SM Ali, M Rosenzweig, J Chmielecki, X Lu, TM Bauer, ...
Go to original source... Go to PubMed, 2015
1152015
Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes
JH Chung, E Sanford, A Johnson, SJ Klempner, AB Schrock, NA Palma, ...
Annals of Oncology 27 (7), 1336-1341, 2016
912016
STUMP un “stumped”: anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features …
V Subbiah, C McMahon, S Patel, R Zinner, EG Silva, JA Elvin, IM Subbiah, ...
Journal of Hematology & Oncology 8, 1-7, 2015
832015
First-in-human phase I study of the tamoxifen metabolite Z-endoxifen in women with endocrine-refractory metastatic breast cancer
MP Goetz, VJ Suman, JM Reid, DW Northfelt, MA Mahr, AT Ralya, ...
Journal of clinical oncology 35 (30), 3391, 2017
812017
Genomic profiling of prostate cancers from men with African and European ancestry
Y Koga, H Song, ZR Chalmers, J Newberg, E Kim, J Carrot-Zhang, D Piou, ...
Clinical Cancer Research 26 (17), 4651-4660, 2020
782020
Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer
R Vatapalli, V Sagar, Y Rodriguez, JC Zhao, K Unno, S Pamarthy, B Lysy, ...
Nature communications 11 (1), 4153, 2020
762020
Integrated analysis of multiple biomarkers from circulating tumor cells enabled by exclusion-based analyte isolation
JM Sperger, LN Strotman, A Welsh, BP Casavant, Z Chalmers, S Horn, ...
Clinical Cancer Research 23 (3), 746-756, 2017
592017
Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration
JA Elvin, LM Gay, R Ort, J Shuluk, J Long, L Shelley, R Lee, ZR Chalmers, ...
The Oncologist 22 (4), 416-421, 2017
562017
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017; 9 (1): 34
ZR Chalmers, CF Connelly, D Fabrizio, L Gay, SM Ali, R Ennis, A Schrock, ...
53
Targeted next generation sequencing identifies markers of response to PD-1 blockade. Cancer Immunol. Res. 2016; 4: 959–967. doi: 10.1158/2326-6066
DB Johnson, GM Frampton, MJ Rioth, E Yusko, Y Xu, X Guo, RC Ennis, ...
CIR-16-0143.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0
48
Comprehensive genomic profiling identifies frequent drug-sensitive EGFR exon 19 deletions in NSCLC not identified by prior molecular testing
AB Schrock, GM Frampton, D Herndon, JR Greenbowe, K Wang, ...
Clinical Cancer Research 22 (13), 3281-3285, 2016
452016
The system can't perform the operation now. Try again later.
Articles 1–20